Royal Bank of Canada’s iRadimed IRMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.87M | Sell |
29,808
-2,970
| -9% | -$297K | ﹤0.01% | 2837 |
|
|
2025
Q4 | $3.19M | Buy |
32,778
+7,825
| +31% | +$671K | ﹤0.01% | 2782 |
|
|
2025
Q3 | $1.77M | Sell |
24,953
-125
| -0.5% | -$8.33K | ﹤0.01% | 3501 |
|
|
2025
Q2 | $1.5M | Sell |
25,078
-704
| -3% | -$38.6K | ﹤0.01% | 3548 |
|
|
2025
Q1 | $1.35M | Buy |
25,782
+3,307
| +15% | +$186K | ﹤0.01% | 3239 |
|
|
2024
Q4 | $1.24M | Sell |
22,475
-899
| -4% | -$47.3K | ﹤0.01% | 3364 |
|
|
2024
Q3 | $1.18M | Buy |
23,374
+4,127
| +21% | +$190K | ﹤0.01% | 3407 |
|
|
2024
Q2 | $846K | Buy |
19,247
+1,381
| +8% | +$58.7K | ﹤0.01% | 3592 |
|
|
2024
Q1 | $786K | Buy |
17,866
+15,447
| +639% | +$683K | ﹤0.01% | 3647 |
|
|
2023
Q4 | $115K | Buy |
2,419
+1,332
| +123% | +$56K | ﹤0.01% | 5530 |
|
|
2023
Q3 | $48K | Buy |
1,087
+600
| +123% | +$27.9K | ﹤0.01% | 5801 |
|
|
2023
Q2 | $23K | Sell |
487
-456
| -48% | -$20.6K | ﹤0.01% | 6143 |
|
|
2023
Q1 | $37K | Sell |
943
-459
| -33% | -$16.7K | ﹤0.01% | 5779 |
|
|
2022
Q4 | $39K | Buy |
1,402
+1,013
| +260% | +$29K | ﹤0.01% | 6027 |
|
|
2022
Q3 | $12K | Buy |
389
+71
| +22% | +$2.47K | ﹤0.01% | 6351 |
|
|
2022
Q2 | $10K | Sell |
318
-337
| -51% | -$12.1K | ﹤0.01% | 6384 |
|
|
2022
Q1 | $29K | Sell |
655
-1,150
| -64% | -$53.2K | ﹤0.01% | 6402 |
|
|
2021
Q4 | $84K | Buy |
1,805
+1,150
| +176% | +$46.4K | ﹤0.01% | 6059 |
|
|
2021
Q3 | $23K | Buy |
655
+179
| +38% | +$6.09K | ﹤0.01% | 6629 |
|
|
2021
Q2 | $14K | Sell |
476
-71
| -13% | -$1.96K | ﹤0.01% | 6736 |
|
|
2021
Q1 | $14K | Buy |
547
+175
| +47% | +$4.18K | ﹤0.01% | 6638 |
|
|
2020
Q4 | $9K | Buy |
372
+342
| +1,140% | +$7.9K | ﹤0.01% | 6427 |
|
|
2020
Q3 | $1K | Hold |
30
| – | – | ﹤0.01% | 6439 |
|
|
2020
Q2 | $1K | Sell |
30
-102
| -77% | -$2.19K | ﹤0.01% | 6438 |
|
|
2020
Q1 | $3K | Hold |
132
| – | – | ﹤0.01% | 6188 |
|
|
2019
Q4 | $3K | Buy |
132
+105
| +389% | +$2.45K | ﹤0.01% | 6486 |
|
|
2019
Q3 | $1K | Hold |
27
| – | – | ﹤0.01% | 6458 |
|
|
2019
Q2 | $1K | Sell |
27
-150
| -85% | -$3.53K | ﹤0.01% | 6706 |
|
|
2019
Q1 | $5K | Sell |
177
-1,189
| -87% | -$31.1K | ﹤0.01% | 6262 |
|
|
2018
Q4 | $34K | Hold |
1,366
| – | – | ﹤0.01% | 5306 |
|
|
2018
Q3 | $51K | Buy |
1,366
+150
| +12% | +$4.05K | ﹤0.01% | 5224 |
|
|
2018
Q2 | $25K | Sell |
1,216
-406
| -25% | -$7.18K | ﹤0.01% | 5440 |
|
|
2018
Q1 | $23K | Hold |
1,622
| – | – | ﹤0.01% | 5401 |
|
|
2017
Q4 | $25K | Sell |
1,622
-6
| -0.4% | -$76 | ﹤0.01% | 5510 |
|
|
2017
Q3 | $16K | Sell |
1,628
-497
| -23% | -$4.71K | ﹤0.01% | 6071 |
|
|
2017
Q2 | $18K | Buy |
2,125
+2,018
| +1,886% | +$17.2K | ﹤0.01% | 5583 |
|
|
2017
Q1 | $1K | Sell |
107
-3,760
| -97% | -$34.9K | ﹤0.01% | 6513 |
|
|
2016
Q4 | $43K | Buy |
3,867
+1,619
| +72% | +$17.4K | ﹤0.01% | 5343 |
|
|
2016
Q3 | $38K | Buy |
2,248
+1,329
| +145% | +$24.6K | ﹤0.01% | 5276 |
|
|
2016
Q2 | $20K | Buy |
919
+86
| +10% | +$1.55K | ﹤0.01% | 5506 |
|
|
2016
Q1 | $16K | Buy |
+833
| New | +$15.9K | ﹤0.01% | 5570 |
|
|
2015
Q4 | – | Sell |
-158
| Closed | -$4K | – | 6731 |
|
|
2015
Q3 | $4K | Sell |
158
-27
| -15% | -$646 | ﹤0.01% | 6223 |
|
|
2015
Q2 | $4K | Buy |
+185
| New | +$3.38K | ﹤0.01% | 6276 |
|
Other funds holding IRMD
CCM
VCM
NTCM
Royal Bank of Canada's IRMD Position: Q1 2026 in Review
Royal Bank of Canada reduced its iRadimed (IRMD) stake by 9.1% in Q1 2026, selling an estimated $297K and leaving 29,808 shares worth $2.87M. The position accounts for ﹤0.01% of the portfolio, ranked #2837.
Royal Bank of Canada first reported a position in IRMD in Q2 2015 and has held it in 43 quarters since. The position peaked at $3.19M in Q4 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.
- Royal Bank of Canada held 29,808 shares of iRadimed worth $2.87M as of Q1 2026.
- Royal Bank of Canada sold 2,970 iRadimed shares in Q1 2026, an estimated $297K.
- iRadimed made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #2837 holding.
- Royal Bank of Canada first reported a position in iRadimed in Q2 2015 and has held it in 43 quarters since.
- Royal Bank of Canada's iRadimed position peaked at $3.19M in Q4 2025.
- 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.